Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Toludesvenlafaxine extended release - Luye Pharma

Drug Profile

Toludesvenlafaxine extended release - Luye Pharma

Alternative Names: 4-Methylbenzoate desvenlafaxine hydrochloride; Anshufaxine hydrochloride extended release - Luye pharma; Ansofaxine hydrochloride extended release - Luye Pharma; Desvenlafaxine prodrug; LPM-570065; LY-03005; Ruoxinlin; Toludesvenlafaxine hydrochloride extended release - Luye Pharma

Latest Information Update: 07 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Luye Pharma Group
  • Class Antidepressants; Anxiolytics; Benzoates; Cyclohexanols; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder
  • Phase III Generalised anxiety disorder

Most Recent Events

  • 07 Sep 2023 Phase-II clinical trials in Major depressive disorder in Japan prior to September 2023 (PO) (Luye Pharma pipeline, September 2023)
  • 12 Jul 2023 Luye Pharma Group initiates phase III clinical trial in Generalised anxiety disorder in China (PO) (NCT05970510)
  • 28 Apr 2023 No recent reports of development identified for clinical-Phase-Unknown development in Major depressive disorder in Europe (PO, Controlled release)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top